Advertisement

Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Debate: should countries bring critical drug production home?

Regulatory breaches at drug manufacturing sites in India and China have fuelled concerns over the safety of the API supply chain and sparked calls for countries to repatriate production of critical medicines. But is this a good idea? Two writers explore the pros and cons of taking back control of API manufacturing.

Close
Close
Close

Go Top